Business Wire

Aleph Farms Unveils Roadmap For Achieving Net Zero Carbon By 2025

3.11.2021 13:03:00 EET | Business Wire | Press release

Share

Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced its detailed roadmap for achieving net zero carbon. In April 2020, Aleph Farms first announced it would reach net zero within its operations by 2025, and throughout its entire supply chain by 2030. Today, Aleph Farms’ net zero carbon roadmap details its scope for achievement, strategic partnerships and the investments necessary to advance its environmental goals and business bottom line as the company delivers its quality cultivated beef steaks.

“The production of food is one of the largest sources of greenhouse gas emissions on the planet today, and a driving reason why Aleph Farms is making long-term sustainability a top priority,” said Dr. Lee Recht, VP sustainability at Aleph Farms. “Our roadmap represents significant research that will enable us to fulfill our commitment to total net zero within this decade and we strongly encourage other companies within the agrifood ecosystem to work to eliminate their carbon footprint as soon as possible.”

Aleph Farms’ roadmap to net zero carbon was created in partnership with Aimee Christensen, CEO of Christensen Global Strategies and a world-renowned expert in climate change and sustainability strategies. The roadmap to reduce the company’s carbon footprint includes optimized energy efficiency, transitioning renewable energy, offsetting and/or insetting unavoidable remaining emissions via reinvestment in decarbonizing Aleph Farms’ own production lines and supply chains.

“By building a company with a net zero mindset from nearly day one, Aleph Farms is pioneering the smart clean growth that all companies must take,” Christensen said. “By investing in energy efficiency and direct renewable energy supplies and similar strategies within its supply chain, Aleph Farms will benefit their bottom line now and even more in the future as carbon is priced around the world.”

As part of its roadmap, Aleph Farms has also signed a Memorandum of Understanding (MoU) with ENGIE Impact, the sustainability consulting arm of ENGIE. The two companies will work together to ensure Aleph Farms’ operations are net-zero compatible from the get-go, integrating energy efficiency, circularity in energy, as well as renewable energy and other strategic investments across Aleph’s production line and supply chains.

“We are delighted to work with Aleph Farms to support their net-zero strategy and vision to transform the meat industry,” said Nicolas Lefevre-Marton, Managing Director, EMEAI at ENGIE Impact. “We are deeply committed to helping bold organizations of all sizes around the world develop the right decarbonization goals, roadmaps and execution strategies to successfully achieve net-zero.”

In addition, Aleph Farms’ commitment to net zero carbon is being supported by a partnership with CE Delft, to analyze the life cycle impacts of Aleph Farms’ production line and supply chain, identifying hotspots and working to optimize the overall ecological footprint including carbon, water, waste and more. CE Delft recently conducted a study that found cultivated meat has the potential to reduce the carbon footprint of beef production by 92% when utilizing renewable sources of energy.

Aleph Farms is co-hosting an event alongside Food Tank at this year’s COP26 in Glasgow, Scotland on November 9, 2021. The panel, A New Approach to Meat, will discuss what it takes to change the production of animal protein and improve environmental impact while maintaining farmers' livelihoods and food security. The company’s white paper, An Inclusive Transition to a Sustainable and Resilient Meat Sector, highlights how transformational net zero carbon production systems can complement sustainable agricultural practices, supplying nutritional food to the growing population and strengthening global food security. To learn more about Aleph Farms' path to sustainability, please visit aleph-farms.com/sustainability.

About Aleph Farms

Aleph Farms grows beef steaks, from non-genetically engineered, non immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram, Twitter, Facebook or LinkedIn or visit www.aleph-farms.com. Access the Aleph Farms press kit here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lizi Sprague
alephfarms@songuepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye